Drugs for Neurilemmoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 64)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Lapatinib |
Approved, Investigational |
Phase 2 |
|
231277-92-2, 388082-78-8 |
208908 |
Synonyms:
FMM
FMM|GW 572016|GW572016|Tykerb®|Tyverb®
GSK-572016
GW 572016
GW-2016
GW572016
GW-572016
GW572016F
GW-572016F
GW-572016X
LAP016
LAPATINIB
LAPATINIB DITOLUENESULFONATE MONOHYDRATE
|
Lapatinib ditosylate
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
N-(3-Chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURANYL]-4-QUINAZOLINAMINE
Tycerb
Tykerb
TYVERB
|
|
2 |
|
Axitinib |
Approved, Investigational |
Phase 2 |
|
319460-85-0 |
6450551 |
Synonyms:
AG 013736
AG 013736|AG-013736|AG013736|Inlyta®
AG013736
AG-013736
AG-13736
|
AXITINIB
AXITINIBUM
INLYTA
N-METHYL-2-({3-[(E)-2-(PYRIDIN-2-YL)VINYL]-1H-INDAZOL-6-YL}SULFANYL)BENZAMIDE
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
|
|
3 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
4 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
5 |
|
Lidocaine |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
137-58-6 |
3676 |
Synonyms:
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
a-Diethylamino-2,6-dimethylacetanilide
ALGRX 3268
ALGRX-3268
ALPHACAINE
alpha-Diethylamino-2,6-dimethylacetanilide
ANESTACON
Astrazeneca brand OF lidocaine
Dalcaine
Dentipatch
Dilocaine
EMBOLEX
IONTOCAINE
Jenapharm brand OF lidocanine hydrochloride
L-Caine
Lidocaina
Lidocaína
LIDOCAINE
Lidocaine carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
|
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
LIDOCATON
Lidoderm
LIDOPEN
Lignocaine
LIGNOCAINE HCL
LIGNOSTAB
LMX 4
Novocol brand OF lidocaine hydrochloride
NSC-40030
Octocaine
ORAQIX
Strathmann brand OF lidocaine hydrochloride
VAGISIL
Xylesthesin
Xylocaine
Xylocaine®
Xylocitin
XYLODASE
Xyloneural
XYLOTOX
ZTLIDO
Α-diethylamino-2,6-dimethylacetanilide
|
|
6 |
|
Doxycycline |
Approved, Investigational, Vet_approved |
Phase 1, Phase 2 |
|
564-25-0 |
54671203 |
Synonyms:
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
5-Hydroxy-a-6-deoxytetracycline
5-Hydroxy-alpha-6-deoxytetracycline
5-Hydroxy-α-6-deoxytetracycline
6a-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
6alpha-Deoxy-5-oxytetracycline
6Α-deoxy-5-oxytetracycline
Anhydrous doxycycline
BMY-28689|Monodox®|Vibramycin®
Doxcycline anhydrous
Doxiciclina
DOXY
Doxychel
Doxycyclin
Doxycycline
|
Doxycycline (anhydrous)
DOXYCYCLINE ANHYDROUS
DOXYCYCLINE HCL
Doxycycline hyclate
Doxycycline hydrate
Doxycycline hydric acid
Doxycycline monohydrate
Doxycycline monohydric acid
Doxycyclinum
Doxytetracycline
GS-3065
Jenacyclin
Monodox
Oracea
Supracyclin
Vibramycin
|
|
7 |
|
Acetylsalicylic acid |
Approved, Vet_approved |
Phase 2 |
|
50-78-2 |
2244 |
Synonyms:
2-(ACETYLOXY)BENZOATE
2-(ACETYLOXY)benzoIC ACID
2-Acetoxybenzenecarboxylate
2-ACETOXYBENZENECARBOXYLIC ACID
2-ACETOXYBENZOATE
2-ACETOXYBENZOIC ACID
2-CARBOXYPHENYL ACETATE
8-HOUR BAYER
A.S.A.
A.S.A. Empirin
ACARD
ACENTERINE
Acesal
Acetal
ACETARD
ACETICYL
Acetilsalicilico
Acetilum acidulatum
Acetisal
ACETOL
ACETONYL
ACETOPHEN
Acetophen®|acetylsalicylic acid|Aspirin®
ACETOSAL
ACETOSALIC ACID
ACETOSALIN
Acetoxybenzoic acid
ACETYLIN
Acetylsal
ACETYLSALIC ACID
ACETYLSALICYLATE
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
ACETYLSALICYLSÄURE
ACETYONYL
ACETYSAL
ACETYSALICYLIC ACID
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
ACIDE 2-(ACÉTYLOXY)BENZOÏQUE
Acide acetylsalicylique
ACIDE ACÉTYLSALICYLIQUE
Acido acetilsalicilico
ÁCIDO ACETILSALICÍLICO
Acido O-acetil-benzoico
ACIDUM ACETYLSALICYLICUM
Acimetten
Acisal
ACYLPYRIN
Adiro
ALKA RAPID
Aloxiprimum
ANADIN ALL NIGHT
ANGETTES 75
ASA
Asagran
ASATARD
Ascoden-30
Aspalon
Aspec
ASPERGUM
ASPIRDROPS
ASPIRIN
Aspirina
Aspirine
Aspro
ASPRO CLR
Asteric
Azetylsalizylsaeure
AZETYLSALIZYLSÄURE
BAY1019036
BAYER EXTRA STRENGTH
Bayer Extra Strength Aspirin For Migraine Pain
BENASPIR
Bialpirina
BIALPIRINIA
Bi-prin
BUFFERIN
CAPRIN
CARDIOASPIRINA
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
DANAMEP
Decaten
Delgesic
Dispril
DISPRIN CV
|
DISPRIN DIRECT
Dolean pH 8
Duramax
DURLAZA
EASPRIN
ECM
ECOLEN
ECOTRIN
EMPIRIN
ENDOSPRIN
ENDYDOL
ENPRIN
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EQUI-PRIN
Extren
GENCARDIA
Globentyl
Globoid
Helicon
Idragin
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LEVIUS
Magnecyl
MAX STRGH ASPRO CLR
MEASURIN
Micristin
MICROPIRIN EC
Neuronika
Novid
NSC-27223
NSC-406186
Nu-seals
NU-SEALS 300
NU-SEALS 600
NU-SEALS 75
Nu-seals aspirin
NU-SEALS CARDIO 75
O-(ACETYLOXY)BENZOATE
O-(ACETYLOXY)BENZOIC ACID
O-accetylsalicylic acid
O-ACETOXYBENZOATE
O-ACETOXYBENZOIC ACID
O-Acetylsalicylate
O-ACETYLSALICYLIC ACID
O-CARBOXYPHENYL ACETATE
O-Carboxyphenyl acetic acid
PAYNOCIL
PERSISTIN
PHARMACIN
Pirseal
PLATET
PLATET 300
Polopirin
POLOPIRYNA
POSTMI 300
POSTMI 75
PREMASPIN
RHEUMINTABLETTEN
RHODINE
Rhonal
Salacetin
SALCETOGEN
SALETIN
Salicylate acetate
SALICYLIC ACID ACETATE
Salicylic acid acetic acid
Salicylic acid, acetate
SALOSPIR
Solfrin
SOLPRIN
SOLPRIN ACID
SOLPYRON
Solupsan
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
TASPRIN
TEMPERAL
TOLDEX
TRIAMINICIN
Triple-sal
Vanquish
VAZALORE
Xaxa
Yasta
Zorprin
|
|
8 |
|
Nimodipine |
Approved, Investigational |
Phase 2 |
|
66085-59-4 |
4497 |
Synonyms:
2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3-beta-methoxyethyl ester 5-isopropyl ester
2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3-b-methoxyethyl ester 5-isopropyl ester
2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3-β-methoxyethyl ester 5-isopropyl ester
2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-beta-methoxyethyl ester 5-isopropyl ester
2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-b-methoxyethyl ester 5-isopropyl ester
2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-methoxyethyl ester 5-isopropyl ester
9736, Bay e
Admon
Almirall brand OF nimodipine
Alpharma brand OF nimodipine
Andromaco brand OF nimodipine
BAY e 9736
BAY-E-9736
BAY-E-9736|Nimotop®
Bayer brand OF nimodipine
Bayvit brand OF nimodipine
Bayvit, nimodipino
Brainal
Calnit
Cantabria brand OF nimodipine
e 9736, Bay
Elan brand OF nimodipine
Esteve brand OF nimodipine
|
Hexal brand OF nimodipine
Hexal, nimodipin
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylic acid
Kenesil
Modus
Nimodipin hexal
Nimodipin isis
NIMODIPINE
Nimodipin-isis
NimodipinISIS
Nimodipino
Nimodipino [INN-Spanish]
Nimodipino bayvit
Nimodipinum
Nimodipinum [INN-Latin]
Nimotop
Nymalize
Periplum
Remontal
Vita brand OF nimodipine
|
|
9 |
|
Crizotinib |
Approved, Investigational |
Phase 2 |
|
877399-52-5 |
11626560 |
Synonyms:
(<i>R</i>)-crizotinib|PF 2341066|PF-02341066|PF-2341066|PF2341066|Xalkori®
(R)-CRIZOTINIB
CRIZOTINIB
Crizotinibum
PF 2341066
|
PF-02341066
PF2341066
PF-2341066
XALKORI
|
|
10 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
11 |
|
Losartan |
Approved |
Phase 2 |
|
114798-26-4 |
3961 |
Synonyms:
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
[<sup>3</sup>H]-losartan
2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
Cozaar
Cozaar®|DuP 753|MK-954
DuP 753
DUP 89
DuP-753
HGP1405
HGP-1405
|
Hyzaar
Lortaan
LOSARTAN
Losartan monopotassium salt
Losartan potassium
Losartic
MK-954
Monopotassium salt, losartan
Potassium, losartan
Salt, losartan monopotassium
|
|
12 |
|
Angiotensin II |
Approved, Investigational |
Phase 2 |
|
68521-88-0, 11128-99-7, 4474-91-3 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
Angiotonin
|
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
13 |
|
Tanezumab |
Investigational |
Phase 2 |
|
880266-57-9 |
|
Synonyms:
|
14 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
15 |
|
Endostatins |
|
Phase 2 |
|
|
|
16 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
17 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
18 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
19 |
|
Endothelial Growth Factors |
|
Phase 2 |
|
|
|
20 |
|
Hormones |
|
Phase 2 |
|
|
|
21 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
22 |
|
Antiprotozoal Agents |
|
Phase 1, Phase 2 |
|
|
|
23 |
|
Antiparasitic Agents |
|
Phase 1, Phase 2 |
|
|
|
24 |
|
Antimalarials |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
26 |
|
Fibrinolytic Agents |
|
Phase 2 |
|
|
|
27 |
|
Antipyretics |
|
Phase 2 |
|
|
|
28 |
|
Cyclooxygenase Inhibitors |
|
Phase 2 |
|
|
|
29 |
|
Platelet Aggregation Inhibitors |
|
Phase 2 |
|
|
|
30 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2 |
|
|
|
31 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
32 |
|
Vasodilator Agents |
|
Phase 2 |
|
|
|
33 |
|
Calcium, Dietary |
|
Phase 2 |
|
|
|
34 |
|
calcium channel blockers |
|
Phase 2 |
|
|
|
35 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
36 |
|
Gelatin Sponge, Absorbable |
|
Phase 2 |
|
|
|
37 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
38 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
39 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
40 |
|
Analgesics |
|
Phase 2 |
|
|
|
41 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
42 |
|
Antibodies |
|
Phase 2 |
|
|
|
43 |
|
Mitogens |
|
Phase 2 |
|
|
|
44 |
|
Antihypertensive Agents |
|
Phase 2 |
|
|
|
45 |
|
Anti-Arrhythmia Agents |
|
Phase 2 |
|
|
|
46 |
|
Angiotensinogen |
|
Phase 2 |
|
|
16133225 |
Synonyms:
Hypertensinogen
Proangiotensin
Renin substrate
Renin substrate tetradecapeptide
|
Renin-substrate
Serpin a8
SERPINA8
Tetradecapeptide, renin substrate
|
|
47 |
|
Angiotensin Receptor Antagonists |
|
Phase 2 |
|
|
|
48 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 2 |
|
|
|
49 |
|
Giapreza |
|
Phase 2 |
|
|
|
50 |
|
Calcium |
Nutraceutical |
Phase 2 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
Interventional clinical trials:
(show top 50)
(show all 79)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With Definite Remaining Vestibular Function |
Withdrawn |
NCT02379754 |
Phase 4 |
Gentamicins |
2 |
Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With no Measurable Remaining Vestibular Function |
Withdrawn |
NCT02415257 |
Phase 4 |
Gentamicin |
3 |
Randomized Comparison of Steretotactic Radiosurgery and Hypofractionated Steretotactic Radiotherapy in the Treatment of Vestibular Schwannoma |
Unknown status |
NCT01449604 |
Phase 3 |
|
4 |
Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping |
Completed |
NCT02104323 |
Phase 2 |
Endostatin |
5 |
Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas |
Completed |
NCT02129647 |
Phase 2 |
Axitinib |
6 |
Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors |
Completed |
NCT00973739 |
Phase 2 |
Lapatinib |
7 |
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas |
Completed |
NCT01125046 |
Phase 2 |
|
8 |
Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma |
Completed |
NCT01207687 |
Phase 2 |
|
9 |
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation |
Completed |
NCT01767792 |
Phase 2 |
Bevacizumab |
10 |
A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma |
Completed |
NCT01490476 |
Phase 2 |
RAD001 |
11 |
Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
Completed |
NCT02934256 |
Phase 2 |
Icotinib |
12 |
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) |
Recruiting |
NCT04374305 |
Phase 2 |
Brigatinib;Neratinib |
13 |
Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2 |
Recruiting |
NCT05521048 |
Phase 1, Phase 2 |
Doxycycline Injection [Doxy] |
14 |
Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors |
Recruiting |
NCT03095248 |
Phase 2 |
Selumetinib |
15 |
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 |
Recruiting |
NCT04351373 |
Phase 2 |
intravenous fluorescein sodium |
16 |
Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas |
Recruiting |
NCT03079999 |
Phase 2 |
Aspirin;Placebo |
17 |
Intraoperative Application of Nimodipine to the Facial and Cochlear Nerves During Vestibular Schwannoma Resection to Avoid Spasm-related Postoperative Facial Paralysis and Deafness - a Prospective Randomized Pilot Study |
Recruiting |
NCT04801953 |
Phase 2 |
NiMODipine Injectable Solution |
18 |
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas |
Active, not recruiting |
NCT04283669 |
Phase 2 |
Crizotinib |
19 |
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis |
Active, not recruiting |
NCT04163419 |
Phase 2 |
Tanezumab;Placebo |
20 |
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma |
Active, not recruiting |
NCT01199978 |
Phase 2 |
Losartan |
21 |
A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma |
Active, not recruiting |
NCT01345136 |
Phase 2 |
RAD001, everolimus |
22 |
Phase II Study of Antineoplastons A19 and AS2-1 in Patients With Neurofibroma and Schwannoma |
Terminated |
NCT02988726 |
Phase 2 |
Antineoplaston therapy (Atengenal + Astugenal) |
23 |
A Phase II Study of Nilotinib in Growing Vestibular Schwannomas |
Terminated |
NCT01201538 |
Phase 2 |
Nilotinib |
24 |
Triamcinolone Acetonide Levels in Cochlear Perilymph, Lateral Canal and CSF in Patients With Vestibular Schwannomas |
Completed |
NCT04658836 |
Phase 1 |
Triamcinolone Acetonide 40mg/mL |
25 |
Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study |
Completed |
NCT01119599 |
Phase 1 |
Gamma-Secretase Inhibitor RO4929097;Temozolomide |
26 |
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET |
Recruiting |
NCT03542773 |
Phase 1 |
18F-DCFPyL Injection |
27 |
Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma (Acoustic Neuroma) |
Suspended |
NCT01083966 |
Phase 1 |
Bevacizumab (Avastin) |
28 |
Novel Multimodality Imaging Techniques for Neurosurgical Planning and Stereotactic Navigation in Lateral Skull Base Surgery: a Feasibility Study |
Unknown status |
NCT04128345 |
|
|
29 |
The Impact of Vestibular Rehabilitation on the Longitudinal Recovery of Laboratory, Clinical, and Community-Based Measures of Head and Trunk Control in People With Acquired Vestibulopathy |
Unknown status |
NCT04594057 |
|
|
30 |
Assessment of the Preoperative Vestibular Rehabilitation Effectiveness on Balance Control Compensation After Vestibular Schwannoma Surgery |
Unknown status |
NCT02275325 |
|
|
31 |
Response Prediction After Gamma Knife Surgery (GKS) in Patients With Vestibular Schwannoma Using Dynamic Contrast-Enhanced (DCE) MR Imaging |
Unknown status |
NCT03097822 |
|
|
32 |
Evolution of Cochleovestibular Schwannomas in the Internal Auditory Canal by Volume Measering With aTeslas MRI 3 |
Unknown status |
NCT04417868 |
|
|
33 |
Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI |
Unknown status |
NCT03593577 |
|
|
34 |
Consequence of Unilateral Vestibular Loss on Visual Abilities |
Unknown status |
NCT03581331 |
|
|
35 |
INTEREST OF INTRAVENOUS INJECTION OF GADOLINIUM IN EXPLORATION INTRA-LABYRINTHINE SCHWANNOMA IN MRI 3 TESLAS |
Unknown status |
NCT03580850 |
|
|
36 |
NF2 Natural History Consortium |
Unknown status |
NCT00004483 |
|
|
37 |
Scleral Hydrops and Intralabyrinthine Schwannoma |
Unknown status |
NCT03581396 |
|
|
38 |
Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery |
Unknown status |
NCT03520829 |
|
|
39 |
Evaluation of the Influence of Psychological Factors on Balance Control Compensation After Vestibular Schwannoma Surgery |
Unknown status |
NCT01743248 |
|
|
40 |
Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma: A Longitudinal Study of Natural History |
Completed |
NCT01951365 |
|
|
41 |
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas |
Completed |
NCT01880749 |
Early Phase 1 |
RAD001 |
42 |
Vestibular Evaluation Before and After Treatment of Vestibular Schwannoma. Comparison of Gamma Knife Radiosurgery and Microsurgical Resection |
Completed |
NCT03670589 |
|
|
43 |
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas |
Completed |
NCT00863122 |
Early Phase 1 |
lapatinib |
44 |
Vestibular Schwannoma - Radiosurgery or Expectation |
Completed |
NCT02249572 |
|
|
45 |
Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma With Pretreatment Prehabituation by Chemical Vestibular Ablation |
Completed |
NCT02963896 |
|
gentamicin |
46 |
Recovery of Visual Acuity in Vestibular Deficits |
Completed |
NCT00411216 |
|
|
47 |
Hippocampal Radiation Exposure and Memory: A Pilot Study |
Completed |
NCT00603694 |
|
|
48 |
Whole Exome Sequencing (WES) of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data |
Completed |
NCT03210285 |
|
|
49 |
Vegetative Monitoring During Brainstem-associated Surgery |
Completed |
NCT03666507 |
|
|
50 |
Alternatives to The Surgical Approach for Giant Spinal Schwannomas: A Clinic Trial |
Completed |
NCT02494622 |
|
|
Cochrane evidence based reviews: neurilemmoma
|